EULAR publishes updated recommendations for treating people with psoriatic arthritis

The European League Against Rheumatism, EULAR, has published updated recommendations on the treatment of people with psoriatic arthritis.
The recommendations are designed to help physicians and health professionals choose the right drug for people with psoriatic arthritis (PsA). Due to the arrival of new drugs, the recommendations have been updated since their last update in 2015.

The overarching principles address the nature of PsA and diversity of both musculoskeletal and non-musculoskeletal manifestations; the need for collaborative management and shared decision-making are highlighted.

The recommendations provide a treatment strategy for pharmacological therapies, which are published in the EULAR Journal, Annals of the Rheumatic Diseases.

Depending on their symptoms, people with psoriatic arthritis should be offered painkillers and if needed local injections of glucocorticoids, then conventional systemic disease-modifying antirheumatic drugs (csDMARDs, such as methotrexate), the next step would be biologic disease-modifying antirheumatic drugs (bDMARDs, such as TNF or IL inhibitors), or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs, such as JAK or PDE4 inhibitors).

Based on updated evidence from a systematic literature review and expert opinion, a EULAR multidisciplinary task force formulated six overarching principles and twelve recommendations. These guidelines aim to help rheumatologists choose the best treatment for each person with this rheumatic condition, based on their individual circumstances.

The six overarching principles are:

• Psoriatic arthritis is a heterogeneous and potentially severe disease, which may require multidisciplinary treatment.
• Treatment should aim at best care and must be based on a shared decision between the patient and the rheumatologist, considering efficacy, safety and costs.
• Rheumatologists should look after the joints of people with psoriatic arthritis; collaboration with a dermatologist is needed if a patient has significant skin disease as well.
• The main goal of treatment is to maximise quality of life by controlling symptoms and preventing structural damage and inflammation
• Each musculoskeletal manifestation should be considered, and treatment decisions made accordingly.

Journal reference:

Gossec, L., et al. (2020) The EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring the link between rheumatoid arthritis and atrial fibrillation